Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Gene Editing and iPS to Study and Treat Monogenic Autoinflammatory Diseases

NCT07889947 is registered in ClinicalTrials.gov with Istituto Giannina Gaslini as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07889947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Gene Editing and iPS to Study and Treat Monogenic Autoinflammatory Diseases
Lead sponsor
Istituto Giannina Gaslini
Phase
Observational
Overall status
Recruiting
Start date
March 25, 2026
Completion date
December 31, 2026
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoinflammatory disease, type 1 interferonopathies

Arms

As registered; 2 arms.

  • A patient with a genetically confirmed diagnosis of STING-associated vasculopathy
  • case controls

Primary endpoints

Registered primary outcome measures; 1 primary.

  • To generate a model of type I interferonopathy to gain insight in STING1 role in nonhematopoietic cells and to explore gene editing as a therapeutic option through study completion, an average of 2 years

Lead sponsor's other trials

Istituto Giannina Gaslini, most recent start first.